Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

September 27, 2021

Amgen receives FDA approval for Repatha to treat paediatric HeFH patients

The US Food and Drug Administration (FDA) has approved Amgen’s Repatha (evolocumab) to treat paediatric patients aged ten years and above with heterozygous familial hypercholesterolemia (HeFH).

Amgen receives FDA approval for Repatha to treat paediatric HeFH patients